Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
161-180 of 991 trials

Hidradenitis Suppurativa: Upadacitinib Study

We are testing Upadacitinib in adults and adolescents with moderate to severe Hidradenitis Suppurativa who haven't responded to other treatments. The goal is to see if it is more effective and safe than a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Advanced Cholangiocarcinoma: Futibatinib Study

We are studying the effects of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. The goal is to see if it helps improve their condition and to understand its safety.

Cholangiocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Fibrotic Interstitial Lung Disease: Morphine for Breathlessness

We are studying whether slow-release morphine can help reduce breathlessness and cough in patients with fibrotic interstitial lung disease. The goal is to see if it improves their overall quality of life.

Fibrotic Interstitial Lung Disease≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Advanced Breast Cancer: Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib

We are studying two treatment combinations for men and women with advanced breast cancer and an ESR1 mutation. The goal is to see which combination helps patients live longer without disease progression.

Metastatic Breast Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Post-Menopausal Osteoporosis: BP16 vs. EU-Prolia

We are comparing a new treatment, BP16, to EU-Prolia for women with post-menopausal osteoporosis. The study looks at how well each treatment improves bone health and their safety.

Post-Menopausal Osteoporosis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Major Depressive Disorder: Lumateperone Study

We are testing lumateperone as an additional treatment for people with major depressive disorder who aren't responding well to their current antidepressants. The study will help us understand its effectiveness and safety.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Mucopolysaccharidosis Type II: DNL310 Treatment Study

We are investigating the long-term safety and effects of DNL310 in patients with MPS II. This study looks at how well the treatment works for cognitive and physical development.

Hunter's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNeurology

Lung Cancer: Zipalertinib Study

We are testing Zipalertinib in patients with advanced non-small cell lung cancer who have specific genetic mutations. The goal is to see if it is safe and effective in treating their condition.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Locally Advanced NSCLC: Alectinib vs. Durvalumab

We are studying whether alectinib or entrectinib is more effective than durvalumab for patients with advanced non-small cell lung cancer who have not progressed after initial treatment. The trial also looks at quality of life and safety for participants.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Anifrolumab for Polymyositis and Dermatomyositis

We are studying whether Anifrolumab can improve muscle strength and reduce corticosteroid use in adults with polymyositis and dermatomyositis compared to a placebo.

Polymyositis and Dermatomyositis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Nipocalimab for Generalized Myasthenia Gravis

We are studying whether nipocalimab IV infusions can help adults with generalized myasthenia gravis perform daily activities better than a placebo. This research aims to assess its effectiveness and safety.

Myasthenia Gravis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Advanced Breast Cancer: Saruparib and Camizestrant Study

We are studying a new combination treatment for adults with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if it helps patients live longer without disease progression compared to standard therapies.

Advanced Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology